MSC Archives | BioInformant

RoosterBio and Qkine Partner to Deliver a Single-Source Platform of Cells, Media, and Growth Factors to U.S. Customers

July 7, 2026 By BioInformant Team Leave a Comment

Distribution agreement gives U.S. customers a single-vendor source for high-quality cells, bioprocess media, and recombinant growth factors—giving cell and exosome therapy developers a single, translation-friendly source for critical raw materials

FREDERICK, MD., July 7, 2026 — RoosterBio, Inc., a leading supplier of cellular starting materials, bioprocess media, and advanced therapy manufacturing solutions for hMSCs, iPSCs, and exosome therapeutic developers, today announced a distribution agreement with Qkine Ltd., a Cambridge, UK–based manufacturer of high-purity, animal origin-free recombinant growth factors, cytokines, and complex bioactive proteins. Under the agreement, customers in the United States can now order Qkine’s full range of translation-friendly research use only (RUO) growth factors and cytokines directly from RoosterBio. [Read more…]

Longevity Medical Institute® Physicians and Scientists Publish Peer-Reviewed Research on Stem Cell Therapies for Diabetic Foot Ulcers

March 10, 2026 By BioInformant Team Leave a Comment

LOS CABOS, BAJA CALIFORNIA SUR, Mexico, March 11, 2026 — Physicians and scientists from Longevity Medical Institute® have published new peer-reviewed research examining the therapeutic potential of allogeneic mesenchymal stem cell therapies for diabetic foot ulcers, one of the most serious and difficult-to-treat complications of diabetes. The publication adds to the growing body of evidence supporting stem cell-based approaches in chronic wound care and reflects Longevity Medical Institute’s broader investment in clinical research, diagnostics, and regenerative medicine infrastructure. [Read more…]

CHU Toulouse and Cell-Easy Launch A-MUSE, a Phase 1/2 Clinical Trial Evaluating the CellReady® Allogeneic MSC Platform in Systemic Sclerosis

January 22, 2026 By BioInformant Team Leave a Comment

Toulouse, January 22, 2026 — Cell-Easy, a CDMO specialized in the development and GMP manufacturing of Advanced Therapy Medicinal Products (ATMPs), announces a new clinical milestone achieved in close collaboration with Toulouse University Hospital (CHU Toulouse). The European Medicines Agency (EMA) has granted Clinical Trial Authorization (CTA) for AMUSE, a Phase 1/2 clinical trial evaluating the safety and efficacy of an allogeneic mesenchymal stromal cell (MSC) therapy in patients with systemic sclerosis presenting perioral fibrosis and functional impairment. [Read more…]

A Spark Becomes a Surge: How Ryoncil Reignited MSC Development

December 18, 2025 By BioInformant Team Leave a Comment

It’s official: Today marks exactly one year since the cell therapy field celebrated a historic milestone. On December 18, 2024, the FDA granted its first-ever approval for a Mesenchymal Stem Cell (MSC) therapy, Mesoblast’s Ryoncil® (remestemcel‑L‑rknd).

This landmark decision marks not just a regulatory first, but a validation of decades of research into the therapeutic potential of MSCs. Once considered experimental, MSC therapies are now stepping into mainstream medicine, signaling the beginning of a new era in regenerative treatments. The approval has ignited renewed investment, scientific exploration, and clinical interest, setting the stage for rapid growth and broader adoption of MSC-based therapeutic products across multiple disease areas. [Read more…]

Patient Enrolment Complete in Phase 2 aGvHD Clinical Trial

December 15, 2025 By BioInformant Team Leave a Comment

Announcement Highlights:

Patient enrolment has been completed in Cynata’s Phase 2 clinical trial of CYP-001 in acute graft versus host disease.
The study has enrolled a total of 65 participants in the US, Europe and Australia, each of whom was randomised to receive either steroids plus CYP-001, or steroids plus placebo.
Primary evaluation period expected to complete in March 2026, with results in June 2026.
CYP-001 has potential to address a major unmet need for the treatment of aGvHD, a life-threatening condition.

[Read more…]